Successful treatment of acute myeloid leukaemia in a patient with ataxia telangiectasia. (18th September 2013)

• Record Type: Journal Article
• Authors: Onoda, Tadashi; Kanno, Miyako; Meguro, Toru; Sato, Hiroko; Takahashi, Noriyuki; Kawakami, Takako; Mitsui, Tetsuo; Hayasaka, Kiyoshi
• Is Part Of: European journal of haematology. Volume 91:Number 6(2013:Dec.)
• Page Start: 557
• Page End: 560
• Publication Date: 2013-09-18
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12186
• Languages: English
• ISSNs: 0902-4441

Abstract

<abstract abstract-type="main" id="ejh12186-abs-0001"> <title>Abstract</title> <p>Ataxia telangiectasia (AT) is a rare autosomal recessive multisystem disorder characterised by cerebellar degeneration, immunodeficiency and cancer predisposition. Around 10% of AT patients develop lymphoid malignancies, but the development of myeloid leukaemia with AT (AT‐AML) is extremely rare, and there have been no previous publications regarding suitable therapies. Here, we first describe a successful therapeutic experience in a patient with AT‐AML (FAB‐M1) who attained remission after induction therapy and maintained stable disease for a year. To minimise therapy‐induced toxicity, low‐dose induction was applied first, though this was obviously insufficient and the patient subsequently responded well to dose‐intensified short‐term chemotherapy. In this report, we suggest a curative therapeutic approach for AT‐AML, though the issue of how best to manage patients with cancer complicated by immunodeficiency remains undecided.</p> </abstract>